img Leseprobe Leseprobe

The Future of HIV-1 Therapeutics

Resistance Is Futile?

Bruce E. Torbett (Hrsg.), Douglas D. Richman (Hrsg.), David S. Goodsell (Hrsg.)

PDF
ca. 96,29
Amazon iTunes Thalia.de Weltbild.de Hugendubel Bücher.de ebook.de kobo Osiander Google Books Barnes&Noble bol.com Legimi yourbook.shop Kulturkaufhaus ebooks-center.de
* Affiliatelinks/Werbelinks
Hinweis: Affiliatelinks/Werbelinks
Links auf reinlesen.de sind sogenannte Affiliate-Links. Wenn du auf so einen Affiliate-Link klickst und über diesen Link einkaufst, bekommt reinlesen.de von dem betreffenden Online-Shop oder Anbieter eine Provision. Für dich verändert sich der Preis nicht.

Springer International Publishing img Link Publisher

Naturwissenschaften, Medizin, Informatik, Technik / Mikrobiologie

Beschreibung

This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.

Weitere Titel in dieser Kategorie
Cover Ion Channels
Novartis Foundation
Cover The New Organon
Francis Bacon

Kundenbewertungen

Schlagwörter

HIV protease, Human immunodeficiency virus, HIV Gag protein, HIV integrase protein, HIV matrix, HIV-1 latency, Fragment-based drug design, HIV reverse transcriptase protein, HIV stem-loop, HIV-1 drug resistance, High-throughput virtual screening, HIV capsid, HIV-1 illustrations, Tat/TAR/P-TEFb complex, Rev protein, HIV transcription, LEDGF/p75 protein, Structure-based drug design, HIV-1 antiretroviral treatment, HIV nucleocapsid protein, antibacterial drug resistance